Catalyst (CPRX) Reports Q4 Earnings: What Key Metrics Have to Say

Group 1 - Catalyst Pharmaceutical (CPRX) reported revenue of $152.61 million for the quarter ended December 2025, reflecting a 7.6% increase year-over-year and a 9% surprise over the Zacks Consensus Estimate of $140.02 million [1] - The earnings per share (EPS) for the quarter was $0.68, down from $0.70 in the same quarter last year, with a significant EPS surprise of +60.95% compared to the consensus estimate of $0.42 [1] - The stock has returned +2.7% over the past month, outperforming the Zacks S&P 500 composite's +0.6% change, and currently holds a Zacks Rank 3 (Hold) [3] Group 2 - Product revenue net for the quarter was $152.5 million, exceeding the average estimate of $140.01 million from four analysts, marking a year-over-year change of +7.5% [4] - FIRDAPSE generated $97.62 million in revenue, surpassing the estimated $96.43 million, representing an 18.3% increase year-over-year [4] - AGAMREE revenue reached $35.3 million, exceeding the average estimate of $31.3 million, with a year-over-year change of +67.5% [4] - FYCOMPA reported revenue of $19.58 million, compared to the average estimate of $12.28 million, indicating a year-over-year decline of -48.8% [4] - License and other revenues were $0.11 million, significantly higher than the estimated $0.03 million, reflecting a remarkable +909.1% change year-over-year [4]